Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation

被引:4
|
作者
Qi, Fei [1 ]
Zhou, Wenyuan [2 ]
Xie, Yan [1 ]
Sun, Yan [3 ]
Wu, Meng [1 ]
Chai, Yue [4 ]
Chen, Bo [5 ]
Lin, Ningjing [1 ]
Liu, Weiping [1 ]
Ding, Ning [1 ]
Li, Yexiong [5 ]
Dong, Mei [4 ]
Song, Yuqin [1 ]
Zhu, Jun [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Nucl Med, Natl Med Prod Adm, NMPA Key Lab Res & Evaluat Radiopharmaceut, Beijing 100142, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Beijing 100142, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Canc Hosp, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China
来源
AGING-US | 2022年 / 14卷 / 21期
基金
中国国家自然科学基金;
关键词
extranodal NK/T-cell lymphoma; induction chemotherapy; response; survival; individualized treatment; BARR-VIRUS DNA; CLINICAL-IMPLICATIONS; PROGNOSTIC-FACTORS; L-ASPARAGINASE; RADIOTHERAPY; RISK; IIE; IE; THERAPY; STRATIFICATION;
D O I
10.18632/aging.204355
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: We aimed to assess the association between induction chemotherapy (CT) response and survivals and to explore an induction CT response-adapted treatment strategy for localized extranodal NK/T-cell lymphoma (NKTCL) receiving first-line sequential CT and radiation (RT). Methods: We retrospectively reviewed the data of patients with localized NKTCL receiving first-line CT+RT from 2010 to 2020 at two independent institutes (primary cohort, n = 203; validation cohort, n = 67). Responses after induction CT (initial response), RT (final response) and survivals were analyzed. Results: Patients with initial complete remission (CR) had higher final CR rate than the others (99.1% vs. 78.7%, P < 0.001). Initial CR was associated with superior 5-year progression-free survival (PFS, 90.0% vs. 61.4% vs. 30.8%, P < 0.001) and overall survival (OS, 93.5% vs. 70.7% vs. 60.6%, P < 0.001), as compared to initial partial remission or non-response. Though majority of cases with initial non-CR achieved final CR after RT, they still had a tendency of shortened OS compared with initial CRs (86.9% vs. 90.6%, P = 0.063). Multivariate analysis demonstrated patients with initial non-CR had higher relapse (HR = 4.748, 95% CI, 2.396-9.407, P < 0.001) and death hazard (HR = 4.296, 95% CI, 1.802-10.24, P = 0.001). Furthermore, more intensive therapy of & GE;6 total cycles of CT yielded significantly superior 5-year OS for patients with initial non-CR (76.7% vs. 54.7%, P = 0.026) rather than patients with initial CR. Conclusion: Deep remission from induction CT was associated with favorable survivals in localized NKTCL receiving CT+RT, and an induction CT response-adapted individualized treatment strategy might be recommended in clinical practice.
引用
收藏
页码:8729 / 8744
页数:16
相关论文
共 50 条
  • [31] Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL)
    Jayoung Lee
    Seok-Goo Cho
    Su-Mi Chung
    Mi Ryeong Ryu
    Sung Hwan Kim
    Hong-Seok Jang
    Byung-Ock Choi
    Annals of Hematology, 2013, 92 : 333 - 343
  • [32] Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma
    Hu, Yunfei
    Chen, Mengxiang
    Song, Yang
    Liu, Xiaomei
    Gou, Feng
    Zhang, Jing
    Huang, Yunhong
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (04): : 257 - 262
  • [33] A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma
    Jiang, Ming
    Zhang, Li
    Xie, Li
    Zhang, Hong
    Jiang, Yu
    Liu, Wei-Ping
    Zhang, Wen-Yan
    Tian, Rong
    Deng, Yao-Tiao
    Zhao, Sha
    Zou, Li-Qun
    ONCOTARGET, 2017, 8 (30) : 50155 - 50163
  • [34] First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG
    Qi, Shu-Nan
    Yang, Yong
    Song, Yu-Qin
    Wang, Ying
    He, Xia
    Hu, Chen
    Zhang, Li-Ling
    Wu, Gang
    Qu, Bao-Lin
    Qian, Li-Ting
    Hou, Xiao-Rong
    Zhang, Fu-Quan
    Qiao, Xue-Ying
    Wang, Hua
    Li, Gao-Feng
    Huang, Hui-Qiang
    Zhang, Yu-Jing
    Zhu, Yuan
    Cao, Jian-Zhong
    Wu, Jun-Xin
    Wu, Tao
    Zhu, Su-Yu
    Shi, Mei
    Xu, Li-Ming
    Yuan, Zhi-Yong
    Su, Hang
    Zhu, Jun
    Li, Ye-Xiong
    BLOOD ADVANCES, 2020, 4 (13) : 3141 - 3153
  • [35] Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma
    Tsai, Hui-Jen
    Lin, Sheng-Fung
    Chen, Chu-Chih
    Chen, Tsai-Yun
    Su, Wu-Chou
    Hwang, Wen-Li
    Lin, Jin-Ching
    Chiou, Tzeon-Jye
    Kao, Weio-Yau
    Chiu, Chang-Fang
    Chang, Yi-Fang
    Chang, Jeffrey S.
    Chang, Ming-Chih
    Su, Ih-Jen
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (02) : 130 - 137
  • [36] Cardiac Involvement in CD56 Negative Primary Pancreatic Extranodal NK/T-cell Lymphoma, Nasal Type, Presenting with Ventricular Tachycardia during the Early Stages of Chemotherapy
    Baek, Yong-Soo
    Shin, Sung-Hee
    Yi, Hyeon-Gyu
    Kim, Dae-Hyeok
    Woo, Seong-Il
    Park, Keum-Soo
    Kwan, Jun
    INTERNAL MEDICINE, 2014, 53 (20) : 2333 - 2336
  • [37] First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ±radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma
    Lee, Keun-Wook
    Yun, Tak
    Kim, Dong-Wan
    Im, Seock-Ah
    Kim, Tae-You
    Yoon, Sung-Soo
    Heo, Dae Seog
    Bang, Yung-Jue
    Park, Seonyang
    Kim, Byoung Kook
    Kim, Noe Kyeong
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1274 - 1282
  • [38] Survival Advantage With the Addition of Radiation Therapy to Chemotherapy in Early Stage Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Zhang, Xi-Mei
    Li, Ye-Xiong
    Wang, Wei-Hu
    Jin, Jing
    Wang, Shu-Lian
    Liu, Yue-Ping
    Song, Yong-Wen
    Fang, Hui
    Ren, Hua
    Zhou, Li-Qiang
    Liu, Xin-Fan
    Yu, Zi-Hao
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (04): : 1051 - 1056
  • [39] A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type
    Ji, Jie
    Liu, Ting
    Xiang, Bing
    Liu, Weiping
    He, Chuan
    Chen, Xinchuan
    Li, Jianjun
    Chang, Hong
    Dai, Yang
    Dong, Tian
    LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2955 - 2957
  • [40] Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
    Yamaguchi, Motoko
    Kwong, Yok-Lam
    Kim, Won Seog
    Maeda, Yoshinobu
    Hashimoto, Chizuko
    Suh, Cheolwon
    Izutsu, Koji
    Ishida, Fumihiro
    Isobe, Yasushi
    Sueoka, Eisaburo
    Suzumiya, Junji
    Kodama, Takao
    Kimura, Hiroshi
    Hyo, Rie
    Nakamura, Shigeo
    Oshimi, Kazuo
    Suzuki, Ritsuro
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4410 - 4416